Recombinant DNA-derived human insulin-like growth factor II (hIGF-II) stimulates growth in hypophysectomized rats.
Sustained subcutaneous administration of recombinant DNA-derived insulin-like growth factor II to immature female hypophysectomized rats stimulated significant increases in body weight gain, tibial epiphyseal cartilage width, femur hydroxyproline concentrations and a significant decrease in serum urea nitrogen concentrations. Recombinant DNA-derived human growth hormone (Humatrope), administered in the same manner produced similar biological effects. The data support the contention that hIGF-II has anabolic effects when administered to hypophysectomized rats and may be a locally acting mediator of pituitary hormone actions.
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.
C J
CJ
Shaar
F C
FC
Tinsley
M C
MC
Smith
J A
JA
Clemens
B L
BL
Neubauer
D000818:Animals; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism; D005260:Female; D006128:Growth / Q000187:drug effects*; D013006:Growth Hormone / Q000494:pharmacology; D006801:Humans; D006909:Hydroxyproline / Q000032:analysis; D007016:Hypophysectomy; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000494:pharmacology; D013002:Somatomedins / Q000494:pharmacology*
D011994:Recombinant Proteins; D013002:Somatomedins; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone; D006909:Hydroxyproline